290 related articles for article (PubMed ID: 21345787)
61. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
62. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
63. Respiratory-gated ¹⁸F-FDG PET/CT for the diagnosis of liver metastasis.
Suenaga Y; Kitajima K; Aoki H; Okunaga T; Kono A; Matsumoto I; Fukumoto T; Tanaka K; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1696-701. PubMed ID: 23768610
[TBL] [Abstract][Full Text] [Related]
64. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
65. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
66. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT.
Tsunoda Y; Ito M; Fujii H; Kuwano H; Saito N
Jpn J Clin Oncol; 2008 May; 38(5):347-53. PubMed ID: 18424814
[TBL] [Abstract][Full Text] [Related]
67. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
68. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
69. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
70. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
71. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
72. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
[TBL] [Abstract][Full Text] [Related]
73. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET.
Chen YK; Chen JH; Tsui CC; Chou HH; Cheng RH; Chiu JS
Radiology; 2011 May; 259(2):525-33. PubMed ID: 21406631
[TBL] [Abstract][Full Text] [Related]
74. 18F-FDG PET/CT for staging of penile cancer.
Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
[TBL] [Abstract][Full Text] [Related]
75. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
[TBL] [Abstract][Full Text] [Related]
76. Autocontouring and manual contouring: which is the better method for target delineation using 18F-FDG PET/CT in non-small cell lung cancer?
Wu K; Ung YC; Hwang D; Tsao MS; Darling G; Maziak DE; Tirona R; Mah K; Wong CS
J Nucl Med; 2010 Oct; 51(10):1517-23. PubMed ID: 20847172
[TBL] [Abstract][Full Text] [Related]
77. Clinical evaluation of PET image reconstruction using a spatial resolution model.
Andersen FL; Klausen TL; Loft A; Beyer T; Holm S
Eur J Radiol; 2013 May; 82(5):862-9. PubMed ID: 23254158
[TBL] [Abstract][Full Text] [Related]
78. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
79. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
80. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
Tochetto SM; Töre HG; Chalian H; Yaghmai V
AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]